OSE Immunotherapeutics SA (EPA:OSE)
France flag France · Delayed Price · Currency is EUR
3.192
-0.014 (-0.44%)
Aug 3, 2026, 4:11 PM CET

OSE Immunotherapeutics Income Statement

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
2.6269.882.2318.326.31
Revenue Growth
-96.25%3037.72%-87.83%-30.43%152.50%
Gross Profit
2.6269.882.2318.326.31
Selling, General & Admin
8.756.536.026.678.61
Research & Development
33.9330.4517.1626.8930.55
Other Operating Expenses
-2.512.722.043.213.77
Total Operating Expenses
40.1839.725.2136.7842.93
Operating Income
-37.5630.18-22.99-18.48-16.63
Interest Income
3.021.72.182.080.27
Interest Expense
-2.94-5.6-2.41-1.62-0.86
Total Non-Operating Income (Expense)
0.07-3.9-0.240.46-0.59
Pretax Income
-37.4139.83-23.22-18.02-17.21
Provision for Income Taxes
0.282.39-0.22-0.26-0.36
Net Income
-37.6937.45-23-17.76-16.85
Net Income to Common
-37.6937.45-23-17.76-16.85
Net Income Growth
-----
Shares Outstanding (Basic)
2222201918
Shares Outstanding (Diluted)
2222201918
Shares Change
2.20%11.48%5.58%2.05%16.71%
EPS (Basic)
-1.691.71-1.18-0.96-0.93
EPS (Diluted)
-1.691.46-1.18-0.96-0.93
EPS Growth
-----

Additional Metrics

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-34.1348.36-19.78-18.53-10.39
Free Cash Flow Growth
-----
Free Cash Flow Per Share
-1.532.22-1.01-1.00-0.57
Gross Margin
100.00%100.00%100.00%100.00%100.00%
Operating Margin
-1434.02%43.19%-1032.15%-100.96%-63.20%
Profit Margin
-1439.06%53.59%-1032.91%-97.04%-64.05%
FCF Margin
-1303.25%69.21%-888.19%-101.22%-39.50%
EBITDA
-34.3133.49-19.46-14.99-13.6
EBITDA Margin
-1310.00%47.92%-873.87%-81.91%-51.70%
EBIT
-37.5630.18-22.99-18.48-16.63
EBIT Margin
-1434.02%43.19%-1032.15%-100.96%-63.20%
Effective Tax Rate
-0.74%5.99%0.94%1.46%2.11%